-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, due to changes in the pharmaceutical environment, it is not uncommon for senior executives of pharmaceutical companies, including general managers, deputy general managers, presidents, and vice presidents, to leave.
high attention
.
Even the founder of medicine has left.
What signal does this send? According to the announcement issued by Jiahe Biology on April 14, Zhou Xinhua decided to resign as the group president and executive director, effective from April 15, 2022
.
Jiahe Bio was established in 2007.
At that time, Zhou Xinhua, who was the scientific director of process development at Amgen in the United States, built a monoclonal antibody drug development and production platform, which is the predecessor of Jiahe Bio
.
In October 2020, Jiahe Biotech landed in the capital market.
There are many shareholders of Hillhouse, Conba, Watson Bio, etc.
, and the company has also received several rounds of financing before
.
However, as a bio-innovative pharmaceutical company, Jiahe Bio has not had a new drug approved for many years until March 2022 when the company announced that the infliximab biosimilar was approved by the State Food and Drug Administration for marketing
.
However, the overall sales of this drug are not large, and the market competition it faces is already very fierce, and similar products have a great impact on it
.
In previous years, the company's revenue was almost zero because no products were listed
.
The financial report shows that the company has a loss of 865 million yuan in 2021, which is narrower than the previous year, mainly due to the one-time change in the fair value of preferred shares in 2020, involving nearly 2 billion yuan
.
The annual report of Jiahe Biology shows that in 2020, Zhou Xinhua's annual salary is as high as 61.
613 million yuan
.
The company said that there was no disagreement between Zhou Xinhua and the board of directors
.
So, what signals are released behind the departure of the founders of innovative pharmaceutical companies? From the perspective of the industry, this means that the innovative drug industry has entered the second half, and the market reshuffle is imminent
.
In recent years, due to the overweight of policies, talents and capital, China's innovative drug market has developed rapidly, but the market competition has become more and more fierce, and pharmaceutical companies generally face the dual pressure of R&D expenditure and commercialization expenditure
.
In the case of PD-1, this type of variety was once the hope of innovative drug companies, but as more and more companies join the field, PD-1 "involution" has become very serious
.
According to incomplete statistics from Southwest Securities, 85 of the 154 PD-1 drugs in the world were developed or jointly developed by Chinese companies, accounting for more than half
.
Judging from the results of the financial report, the domestic PD-1 market size has changed from what it used to be.
In addition to imported products, the overall domestic PD-1 market sales do not exceed 15 billion yuan
.
In order to avoid "involution", some PD-1 companies are also expanding their indications and actively "going overseas", trying to make up for a little "blood" in research and development, but overall, the entire track is getting more and more crowded, and those who want to share The difficulty is also increasing
.
At present, a series of domestic new medical policies are releasing signals to encourage and support true innovation and combat "pseudo-innovation".
The Notice of Opinions on Guiding Principles for Clinical Research and Development of Antitumor Drugs emphasizes that drug research and development should be guided by clinical value, which will "squeeze out" the valuation bubble of innovative drugs to a certain extent
.
However, at this stage, domestic innovative drug companies mainly focus on improved innovation and biosimilar drugs, and their sustainability is generally weak
.
The industry believes that the road ahead of pseudo-innovation is not easy, and it is difficult to go far.
Therefore, pharmaceutical companies still need to have the hard power of innovation in order to make some achievements in this arena
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
high attention
.
Even the founder of medicine has left.
What signal does this send? According to the announcement issued by Jiahe Biology on April 14, Zhou Xinhua decided to resign as the group president and executive director, effective from April 15, 2022
.
Jiahe Bio was established in 2007.
At that time, Zhou Xinhua, who was the scientific director of process development at Amgen in the United States, built a monoclonal antibody drug development and production platform, which is the predecessor of Jiahe Bio
.
In October 2020, Jiahe Biotech landed in the capital market.
There are many shareholders of Hillhouse, Conba, Watson Bio, etc.
, and the company has also received several rounds of financing before
.
However, as a bio-innovative pharmaceutical company, Jiahe Bio has not had a new drug approved for many years until March 2022 when the company announced that the infliximab biosimilar was approved by the State Food and Drug Administration for marketing
.
However, the overall sales of this drug are not large, and the market competition it faces is already very fierce, and similar products have a great impact on it
.
In previous years, the company's revenue was almost zero because no products were listed
.
The financial report shows that the company has a loss of 865 million yuan in 2021, which is narrower than the previous year, mainly due to the one-time change in the fair value of preferred shares in 2020, involving nearly 2 billion yuan
.
The annual report of Jiahe Biology shows that in 2020, Zhou Xinhua's annual salary is as high as 61.
613 million yuan
.
The company said that there was no disagreement between Zhou Xinhua and the board of directors
.
So, what signals are released behind the departure of the founders of innovative pharmaceutical companies? From the perspective of the industry, this means that the innovative drug industry has entered the second half, and the market reshuffle is imminent
.
In recent years, due to the overweight of policies, talents and capital, China's innovative drug market has developed rapidly, but the market competition has become more and more fierce, and pharmaceutical companies generally face the dual pressure of R&D expenditure and commercialization expenditure
.
In the case of PD-1, this type of variety was once the hope of innovative drug companies, but as more and more companies join the field, PD-1 "involution" has become very serious
.
According to incomplete statistics from Southwest Securities, 85 of the 154 PD-1 drugs in the world were developed or jointly developed by Chinese companies, accounting for more than half
.
Judging from the results of the financial report, the domestic PD-1 market size has changed from what it used to be.
In addition to imported products, the overall domestic PD-1 market sales do not exceed 15 billion yuan
.
In order to avoid "involution", some PD-1 companies are also expanding their indications and actively "going overseas", trying to make up for a little "blood" in research and development, but overall, the entire track is getting more and more crowded, and those who want to share The difficulty is also increasing
.
At present, a series of domestic new medical policies are releasing signals to encourage and support true innovation and combat "pseudo-innovation".
The Notice of Opinions on Guiding Principles for Clinical Research and Development of Antitumor Drugs emphasizes that drug research and development should be guided by clinical value, which will "squeeze out" the valuation bubble of innovative drugs to a certain extent
.
However, at this stage, domestic innovative drug companies mainly focus on improved innovation and biosimilar drugs, and their sustainability is generally weak
.
The industry believes that the road ahead of pseudo-innovation is not easy, and it is difficult to go far.
Therefore, pharmaceutical companies still need to have the hard power of innovation in order to make some achievements in this arena
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
